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Abstract
Alzheimer’s disease (AD) is the most common cause of dementia among older people. At present, there is no cure for the
disease and as of now there are no early diagnostic tests for AD. There is an urgency to develop a novel promising
biomarker for early diagnosis of AD. Using surface-enhanced laser desorption ionization-mass spectrometry SELDI-(MS)
proteomic technology, we identified and purified a novel 11.7-kDa metal- binding protein biomarker whose content is
increased in the cerebrospinal fluid (CSF) and in the brain of AD dementia subjects as a function of clinical dementia.
Following purification and protein-sequence analysis, we identified and classified this biomarker as S100A7, a protein
known to be involved in immune responses. Using an adenoviral-S100A7 expression system, we continued to examine the
potential role of S100A7 in AD amyloid neuropathology in in vitro model of AD. We found that the expression of exogenous
S100A7 in primary cortico-hippocampal neuron cultures derived from Tg2576 transgenic embryos inhibits the generation of
b-amyloid (Ab)1–42 and Ab1–40 peptides, coincidental with a selective promotion of ‘‘non- amyloidogenic’’ a-secretase
activity via promotion of ADAM (a disintegrin and metalloproteinase)-10. Finally, a selective expression of human S100A7 in
the brain of transgenic mice results in significant promotion of a-secretase activity. Our study for the first time suggests that
S100A7 may be a novel biomarker of AD dementia and supports the hypothesis that promotion of S100A7 expression in the
brain may selectively promote a-secretase activity in the brain of AD precluding the generation of amyloidogenic peptides.
If in the future we find that S1000A7 protein content in CSF is sensitive to drug intervention experimentally and eventually
in the clinical setting, S100A7 might be developed as novel surrogate index (biomarker) of therapeutic efficacy in the
characterization of novel drug agents for the treatment of AD.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
among people age 65 and older. AD affects approximately 4
million Americans, of which nearly half are in health care
institutions [1]. Both neuritic senile plaques (NPs) and neurofibril-
lary tangles (NFTs) are the pathological hallmarks of the disease,
with progressive loss of neurons in the brain. In some vulnerable
brain regions, such as certain cortical areas, more than 50% or
even up to 70%–90% of neurons are lost [2]. As a result, a
diseased brain may show overall shrinkage, severe cortical
atrophy, and ventricular enlargement in late stages of the disease
[3].
At present, there is no cure for the disease and early diagnosis is
all but impossible. The onset of disease is not manifested clinically
and little is known regarding the cause of non-familiar AD. There
is also no definite clinical method to determine in which patients
with mild cognitive impairment progresses to AD with dementia
[4–5]. Therefore, there is an urgency to develop a novel promising
biomarker for early diagnosis of AD [4].
AD often goes unrecognized or is misdiagnosed in its early
stages, often because its symptoms are mistaken for inevitable
consequences of aging. Even as the disease progresses, clinical
diagnosis can be made with only 65%–90% accuracy. A definitive
diagnosis of AD can only be made after death, when autopsy can
reveal senile plaques and neurofibrillary tangles in brain tissue.
The plaques result from aggregation of b-amyloid peptides and
were thought to be involved in the pathogenesis of AD; however,
their presence does not always correlate with neurologic symptoms
[6]. Identification of an AD biomarker for early clinical AD
diagnosis is a critical first step in the development of methodologies
for early disease intervention, and would have several advantages.
It would be able to identify AD at a very early stage of the disease,
before the cognitive symptoms are found in neuropsychologic tests,
and before brain-imaging studies could reveal degeneration.
Differential diagnosis of AD is difficult, and a biomarker reflecting
neuropathologic changes at the molecular level in the brain could
distinguish AD patients not only from those individuals with mild
cognitive impairment who do not develop AD but also from
patients with depression. A biomarker would also greatly help
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neuropathological changes. Until now, AD cannot be diagnosed
by a valid clinical method or a biomarker before the disease has
progressed so far that dementia is present. Furthermore, no valid
method is available to determine which patient with mild cognitive
impairment (MCI) will progress to AD. Therefore, a correct
diagnosis in the early stage of AD is not only of importance
considering that early drug treatment is more effective but also
that the psychological burden of the patients and relatives could be
decreased [7].Many ante-mortem biochemical markers for AD
have been investigated. Plasma, erythrocytes [8], lymphocytes [9],
urine [10], hair [11], and skin [12], have all been analyzed.
Clinical trials of novel therapeutic strategies in AD are
disadvantaged by our lack of understanding of the pathophysiol-
ogy of AD. Because AD cannot be diagnosed until well into the
disease cycle, clinical trials with potential novel disease-modifying
drugs are conducted in advanced AD dementia cases, which often
mean that the disease is too far along for the agents to have much
effect. In addition, there is the lack of understanding in the
mechanism that supports application of specific drugs and the lack
of a rational dose and clinical stage of AD for application of novel
drugs to treatment populations. Further characterization of novel
indexes of AD clinical progression and pathophysiology may
provide insight that might facilitate the development of ‘‘custom-
ized’’ therapeutic intervention for specific stages of the disease.
Because AD is sometimes undiagnosed or misdiagnosed, it is
extremely important to identify robust and easily measured
biological markers for the disease, especially markers that detect
early or impending disease. Such a panel of markers could allow
for early therapeutic treatment intervention to potentially restore
memory formation, stop the deposition of insoluble amyloid-beta
plaques and prevent neurodegeneration. Biomarkers may also
allow real-time testing to monitor whether disease progression has
been changed by therapeutic interventions [13].
In this study using proteomic approaches we report for the first
time the identification and characterized of a protein S100A7
previously implicated in inflammatory responses and cell differ-
entiation among other functions [26] in the CSF and brain of AD.
We sought to understand how S100A7 may influence AD clinical
dementia, and found that S100A7 may selectively attenuate AD
amyloid neuropathology through promotion of the ‘‘non-amyloi-
dogenic’’ a-secretase processing of APP.
Materials and Methods
Protein profiles in AD CSF and serum using SELDI MS
All individuals underwent evaluation that consisted of medical
history, physical and neurologic examinations, laboratory tests,
and neuropsychological assessments. Control subjects had no signs
or symptoms of cognitive decline or neurologic disease including
epilepsy; all subjects had a MMSE score between 28 and 30; a
CDR score of 0; and NYU paragraph recall scores (immediate and
delayed) .6. Lumbar puncture (LP) was performed with a 24G
spinal needle. Individuals remained at bed rest for one hour
following LP. Only AD patients with pathological confirmation of
AD according to NIA-Reagan criteria (high), to the exclusion of
Lewy body disease or vascular disease were included in this study.
All CSF for proteomic analysis was taken from the 15
th to 25
th ml
collected to limit variations arising from rostral-caudal gradient. In
addition, all LP was performed in the morning to limit potential
circadian fluctuation of CSF proteins and metabolites. Clear CSF
specimens were collected and immediately frozen and stored at
270uC. The protein concentration in CSF is relatively low
compared to plasma (CSF:plasma=1/20–100), and in addition,
the protein profiles in CSF are similar to those in plasma,
suggesting that even a minor contamination of CSF with blood
could significantly confound the interpretation of quantitative
proteomic analysis of CSF. To minimize blood contamination in
our CSF samples, only CSF samples with ,10 RBCs/ml and a
serum: CSF ApoB (a protein not generated in CNS) CSF protein
expression profiles were analyzed using high-throughput SELDI
mass spectrometry. Control samples were always run in parallel
with the experimental samples and the signals in the resulting
profiles of each chip were simultaneously normalized and
represented individually, via integrated software, allowing for
direct comparison of individual protein expression profiles. All
samples for the proposed study were obtained from Dr. Elaine
Peskind at University of Washington (UW). In order to provide
protection to research subjects, it is policy at UW to obtain
‘‘double consent’’ from both the subject and their legally
authorized representative when the subject is a member of a
cognitively impaired group. The standard procedure at UW is that
all subjects with cognitive impairment have a legally authorized
representative (using Washington statutory definition) co-sign all
consents. We attempt to protect each subject’s rights and welfare
by explaining to both the subject and the person with signing
authority that this study is voluntary, they will not lose any other
benefits to which they are otherwise entitled by not participating,
that there are risks associated with this research, and that if they
are not currently taking one of the FDA-approved drugs for
treatment of dementia that they may want to consider trying one
of these prior to getting involved with this study.
In all cases, we make sure that a subject with cognitive
impairment is manifesting assent before beginning or continuing
any study procedure (whether it be as minor as taking vital signs or
as major as performing an LP). If at any time, a subject with
cognitive impairment expresses desire to skip or discontinue a
study procedure, we respect that subject’s wishes. Because people
with cognitive impairment sometimes have difficulty verbally
expressing themselves, if there is any indication at any time during
the study, verbally or physically, that they do not want to
participate, we will discontinue them. The only exception would
be that if a subject with cognitive impairment wishes to leave the
Clinical Research Unit before it is appropriate (i.e., after the LP,
we prefer to have the subject lie in bed for one hour to minimize
any potential for side effects). In such a case, we would do our best
to have the subject continue study protocol as much as possible.
The Institutional Review Board of the University of Washington
approved the use of human subjects for this study.
In this study, human CSF samples were analyzed using two
types of ProteinChips: Immobilized Metal Affinity Capture
(IMAC) chips and Strong Anion Exchange (SAX) chips, which,
respectively, selectively capture divalent metal-binding proteins
and anionic (basic) proteins for analysis by ‘‘time of flight’’ mass
spectrometry. For SELDI analysis using the IMAC chip, an eight-
spot IMAC chip was first activated by incubating twice (15 min
each) with copper sulfate (100 mM in water). The chip was then
washed with water, followed by washing with sodium acetate
(50 mM in water) and a final wash with water. The chip was then
assembled with a ‘‘Bioprocessor’’ (Bio-Rad), which allows for
applications of large volumes onto each of the ProteinChip spots,
and individual CSF samples were immediately applied over each
of the spots. In this study, independent CSF specimens containing
1 mg of total protein were adjusted to a final volume of 120 ml
PBS/0.1% Triton-X 100 for SELDI analysis. Samples were
shaken (250 rpm) for 1 hour at room temperature. The Pro-
teinChip was washed three times (5 min each) with PBS
containing 0.1% Triton-X 100 followed by a quick rinse with
S100A7 as Activator of ADAM10
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sinapinic acid (SPA) solution (in 50% acetonitrile/0.5% trifluor-
oacetic acid) was applied on each spot. After drying, the profile of
divalent metal-binding proteins captured on each of the spot was
analyzed by ‘‘time of flight’’ mass spectrometry using a PBS II
ProteinChip reader system (Bio-Rad).
For selective capturing and expression-profile analysis of anionic
protein species from CSF, 2 mg of total protein from individual
specimen was adjusted to a final volume of 200 ml with binding
buffer [20 mM Trisma base (pH 8) containing 0.1% Triton-X
100]. A SAX ProteinChip was assembled with a ‘‘Bioprocessor’’
and each spot was prewashed (shaking at 250 rpm for 5 min at
room temperature) with 350 ml of 20 mM Trisma base (pH 8)
containing 5 M NaCl and 0.1% Triton-X 100. Thereafter, the
prewash solution is exchanged with CSF samples following by
incubation (shaking at 250 rpm at room temperature) for 1 hour.
The chip was washed 3 times (5 min each) with binding buffer
followed by a brief rinse with water. SPA (1 ml) was applied to each
spot and anionic proteins captured on to each of the spots were
analyzed using the PBS II system. In all SELDI ‘‘time of flight’’
mass spectrometry analysis using either the IMAC or the SAX
ProteinChip, individual protein-expression profile spectra were
collected using an average of 80 laser shots (with the laser intensity
set at 180, and detector sensitivity set at 6 on the PBS II system).
Spectra collected were analyzed using the ProteinChip software
version 2.1c, which highlights differences in expressions of specific
protein species [defined by mass (Da)/charge] between treatment
groups (e.g., CSF from animals treated with FCA vs. animals
treated with FCA plus nimesulide).
ELISA measurement of S100A7 protein in CSF
CSF samples were coated in Nunc-Immuno plates (Maxisorp,
Nunc, Roskilde, Denmark) in 100 ml of Buffer 42 (30 mM
NaHCO3,7 0m MN a 2CO3, 0.05% NaN3, pH 9.6) at 4uC for
O/N. The antigen from the wells was aspirated and tapped on
absorbent paper to remove excess liquid. It was washed well with
400 ml PBS, incubated for 15–30 seconds, aspirated, and then
repeated once. The plate was blocked with 300 ml of blocking
solution (TBS+0.1%Tween+5%milk) and incubated for 1–2 hours
at room temperature with rocking. Blocking solution was removed
and incubated with S100A7 monoclonal antibody (1:500)
(Imgenex, San Diego, CA) for 2 hours. The microplates were
washed 4 times with 400 ml per well of PBST. Wells were
incubated with 100 ml of diluted horseradish peroxidase-conju-
gated mouse IgG (1:2000) at room temperature for 2 hours. The
microplates were washed 4 times with 400 ml per well of PBST.
TMB [Microwell Peroxidase Substrate System, Kirkegaard &
Perry Laboratories, Maryland, USA] were added (100 ml). Plates
were allowed to develop until the second to the least concentration
standard had a slight color change; the reaction was then stopped
by adding 100 ml 1.8 N H2SO4 (10% H2SO4 or 5.7% O-
phosphoric acid) to each well. The plates were read plates at
450 nm within 30 min of adding the solution.
Postmortem AD brain
Human postmortem brain samples from AD and age-matched
non-AD cases were obtained from the Alzheimer’s Disease Brain
Bank of the Mount Sinai School of Medicine. The cases selected
had either no significant neuropathological features or only
neuropathological features associated with AD. A multistep
approach based on cognitive and functional status during the last
6 months of life was applied to the assignment of clinical dementia
rating (CDR). Samples of OC and EC were divided into groups on
the basis of their CDRs as follows (OC/EC): CDR 0, non-
demented (n=9/9); CDR 0.5, at high risk of developing AD
dementia (n=14/9); and CDR 5, severe dementia (n=9/9).
The extent of amyloid neuritic plaques (NPs) and neurofibrillar
tangles (NFTs) staining in the EC-BM36/38 was assessed in
accordance with the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) neuropathologic battery [14].
Multiple (,5) high-power (6200, 0.5-mm
2) fields were examined
in each histologic slide from multiple regions of tissue, according to
the CERAD regional sampling scheme. The density of NPs and
NFTs was rated on a 4-point scale as follows: 0, absent; 1, sparse;
3, moderate; and 5, severe. Plaques were visualized after either
Bielschowsky silver or thioflavin-S staining. Three of the
investigators were masked to the clinical diagnosis of each patient
until all quantitative analyses were complete and values were
assigned to each specimen.
Detection of human S100A7 mRNA expression by RT-PCR
assay
Quantitative human S100A7 real-time (RT)-PCR was conduct-
ed as previously described, with minor modifications [15]. Briefly,
total RNA was extracted from frozen brain tissue samples (Qiagen,
Valencia, CA) and transcribed into cDNA by 40 rounds of PCR
amplification in the presence of SYBR Green I (Molecular Probes,
Eugene, OR), human S100A7 primers (forward primer: 59-AGC
CTC AAA CTC CAA ACA CC-39 and reverse primer: 59-CAA
CAG GGA TTT GAC CAC-39); using an ABI 7900HT thermal
cycler (Applied Biosystems, Foster City, CA) at 95uC for 15 sec
(denaturation), 55uC for 15 sec (annealing), and 72uC for 30 sec
(extension).
Amplicon size and reaction specificity was confirmed by agarose
gel electrophoresis. CTGF RT-PCR amplification was monitored
in real time following each thermal cycle by measurements of
fluorescent emission generated by incorporation of SYBR Green
into double-stranded DNA. Data were transformed into a semi-log
plot where the X-axis represents PCR cycle number and the Y-
axis represents the log value of fluorescent intensity. For each
reaction, the threshold cycle (CT), which is the number of PCR
cycles corresponding to the detection threshold, was obtained. The
copy number of the targeted gene in each sample was interpolated
from its median CT values using a standard curve derived from
parallel quantitative RT-PCR amplification of purified CTGF
PCR product.
Generation of human (h) S100A7 adenoviruses
To generate human h-S100A7 adenoviruses, h-S100A7 cDNA
construct was introduced to the Adeno-X
TM genome for
generation of recombinant Adeno-X virus, according to the
Adeno- X
TM expression system manual (Clontech, Palo Alto, CA).
Briefly, the full-length S100A7 cDNA was subcloned into the
pShuttle vector cassette via XbaI and KpnI. Both pShuttle/h-
S100A7 were then transferred into the Adeno-X viral DNA via I-
CeuI and PI-CseI sites; the identity of the h-S100A7 -Adeno-X
viral DNA was confirmed by nucleotide sequencing. The
recombinant viruses were then packaged by transfecting PacI
linearized recombinant viral DNA into human embryonic kidney
(HEK) 293 cells with the aid of Lipofectamine (Gibco, Rockville,
MD). h-S100A7 Adeno-X viral titer was determined by the tissue-
culture infectious dose 50 (TCID50) method [16]. This identical
strategy was used to generate recombinant LacZ-adenovirus
(Clontech, Palo Alto, CA) expressing the bacterial b-galactosidase
gene (Clontech, Palo Alto, CA), which served as a negative
control. All protocols for viral studies were approved by the Mount
Sinai Institutional Review Board.
S100A7 as Activator of ADAM10
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Chinese Hamster Ovary (CHO) cells expressing human
amyloid precursor protein (APP) carrying the K670N, M671L
Swedish mutation (APPswe) (CHO-APPswe; gift from Dr. Robakis)
were grown in McCoy’s 5A medium supplemented with 10% fetal
bovine serum, 1% streptomycin/penicillin (GIBCO), and 400 mg/
ml G418 (Life Technologies, Carlsbad, CA). For viral infection,
CHO-APPswe was seeded at 4610
4 cells/cm
2 and cultured at
37uC in the presence of 5% CO2. Following 24 hours of
incubation, cultures (50% confluence) were infected with recom-
binant h-S100A7 or LacZ adenovirus with doses of virus defined
as 10 multiplicities of infection (MOI) [17]. Conditioned medium
was collected 24 or 48 hours postinfection for amyloid-beta
detection. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay of
the cell lysate, as previously described [18].
Primary neuronal cultures
Embryonic (E14) cortico-hippocampal primary neuronal cul-
tures derived from heterozygous Tg2576 transgenic mice were
prepared as previously described [19]. Briefly, after brain
dissection, mechanical trituration, and centrifugation, neurons
were seeded onto poly-D-lysine–coated 12-well plates at a density
of 1610
6 cells per well and cultured in neurobasal/B27 medium.
The absence of astrocytes (,1–2%) was confirmed by the lack of
glial fibrillary acidic protein (GFAP) immunostaining verified in
parallel studies (data not shown).
All mice protocols were approved by the Mount Sinai
Institutional Animal Care and Use Committee.
S100A7, sAPPa, sAPP total, holo APP, ADAM-10, ADAM-9,
TACE (ADAM-17), MAPK, and PKC immunodetection
Following adenoviral infection and/or incubation with drugs for
the appointed time, conditioned media was collected and tissue
cultures lysed in RIPA buffer (16PBS, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 0.1 mM EDTA) in the presence of
a protease-inhibitor cocktail (Sigma, St Louis, MO) on ice, and
stored at 220uC. For immunoblot analysis, protein content was
determined by Bradford method (Bio-Rad, Hercules CA), samples
were boiled, centrifuged and proteins resolved electrophoretically
by SDS-PAGE (10%). Proteins were transferred to nylon transblot
membranes (Bio-Rad) and immunoreacted with appropriate
antibody. In these studies immunoreactivities were visualized by
fluorescence autoradiography using ECL chemiluminescence
detection (SuperSignal Chemiluminescent Detection Kit, Pierce
Biotechnology, Rockford IL).
Monoclonal S100A7 was used at 1:500 dilution (Imgenex, San
Diego, CA). Polyclonal C8 antibody (1:1,000 dilution, raised
against amino acids 676–695 of human APP, a gift from Dr.
Selkoe) was used for detection of total human holo-APP.
Monoclonal 22C11 antibody (1:1,000 dilution, Chemicon Inter-
national, Temecula, CA) recognizing amino acids 60–100 of an N-
terminal epitope of human APP was used to quantify total soluble
(s)APP. Monoclonal 6E10 antibody (1:1,000 dilution, Senetek, St.
Louis, MO) recognizing amino acids 1–17 of the b-amyloid
domain of APP (a site that constitutes the C terminus of sAPP
peptide) was used to quantify the level of sAPPa. Polyclonal
ADAM-10 (1:500 dilution, Chemicon, CA), polyclonal ADAM9
antibody (1:500 dilution, Chemicon International, Temecula, CA),
polyclonal TACE antibody (1:1,000 dilution, Santa Cruz Biotech-
nology, CA), polyclonal BACE (M-83) antibody (1:200 dilution,
Santa Cruz Biotechnology, CA), and polyclonal anti-IDE
antibodies (clone BC2 1:500 dilutions, gift from Dr. Eduardo
Castano) were used for detection of the levels of ADAM-10,
ADAM-9, TACE (ADAM-17), BACE and IDE, respectively. In
these studies b-actin immunoreactivity (1:3,000 dilution, Sigma,
MO) controlled for selectivity of changes.
Measurement of a-secretase and b-secretase activity
a-secretase and b-secretase activities were measured using
commercially available kits (R & D Systems, Minneapolis, MN).
Briefly, cultured cells or brain samples were homogenized in
supplied buffers. The homogenate containing 200 mg total protein
was then added to alpha-secretase–specific APP peptide
(YEVHHQKLV for alpha-secretase activity assay and REEVNL-
DAEFKR for beta-secretase activity assay) conjugated to the
reporter molecules EDANS and DABCYL. In the uncleaved form,
the fluorescent emissions from EDANS are quenched by the
physical proximity of the DABCYL moiety, which exhibits
maximal absorption at the same wavelength (495 nm). Cleavage
of the peptide by the secretase physically separates the EDANS
and DABCYL, allowing for the release of a fluorescent signal. This
signal may be quantitated at an excitation/emission wavelength of
355/510 nm. The level of secretase enzymatic activity in the
homogenate is proportional to the fluorometric reaction (R&D
Systems).
CTF-c assay
In h-S100A7 or LacZ-infected cells, levels of CTF-c cleavage
product of APP were assessed from membrane preparations, as
previously described [20–23]. Briefly, cell monolayers were rinsed
twice with ice-cold PBS on ice, scraped from tissue-culture dishes
and centrifuged (1,500 rpm, 10 min, 4uC). Cell pellets were then
resuspended (0.5 ml/10 cm dish) in homogenization buffer
[10 mM MOPS, pH 7.0, 10 mM potassium chloride, 16
complete protease inhibitor (PI)] (Roche Molecular Biochemicals,
Germany), and homogenized by passing cell suspensions through a
23-gauge needle 10 times. Homogenates were then centrifuged
(2,500 rpm, 15 min at 4uC) to remove unbroken cells and nuclei.
The supernatant (membrane and postnuclear supernatant) was
then centrifuged (14,000 rpm, 20 min, 4uC) and rinsed in
homogenization buffer. Membranes were then resuspended in
assay buffer (150 mM sodium citrate pH 6.4; 16 PI) and
incubated (2 hr) at 37uCi n2 5ml of incubation buffer per assay
sample to allow for generation of the CTF-c cleavage product;
negative control samples were maintained on ice. CTF- c cleavage
products (as well as CTF-a and CTF-beta) were resolved
electrophoretically in 10–20% Tris-Tricine gels (Bio-Rad, CA),
and identified using the anti APP polyclonal C8 antibody.
Immunoreactivities were visualized autoradiographically using a
chemiluminescence detection kit (SuperSignal; Pierce Biotechnol-
ogy, Rockford, IL).
Ab ELISA assays
For detection of b-amyloid peptide generation, conditioned
media from CHO-APPswe cells were centrifuged (3,5006g,
10 min, 4uC) to remove cellular debris. b-amyloid1–40 or b-
amyloid1–42 was assessed by sandwich ELISA, according to
manufacturer’s instructions (BioSource, Camarillo, CA).
S100A7 cell-surface receptor assessment
For the study exploring the presence of cell-surface S100A7
receptors we used an alkaline phosphatase (AP)–S100A7 fusion
protein as a ligand. To generate the AP–PIF fusion protein, a
cDNA encoding the entire mature human S100A7 protein was
introduced into the 39-poly-linker site of the AP-TAG-5 expression
S100A7 as Activator of ADAM10
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domain. This recombinant AP-S100A7 construct was transiently
transfected into HEH 293 with the aid of Lipofectamine (Life
Technologies, Rockville, MD). The AP-S100A7 construct directs
the expression of an N-terminal alkaline phosphatase (AP) C-
terminal S100A7 fusion protein, which is secreted into the culture
medium. Condition medium was collected 3 days after transfec-
tion for in situ staining of S100A7 receptor. Comparable strategies
will be used to generate AP as a negative control for in situ staining
studies. The AP-S100A7 fusion protein was used to identify
S100A7-receptor in mouse brain, primary mouse neuron culture,
CHO-APPswe cells, and platelets as described [24–25]. For the
frozen brain-tissue sections, specimens were cryosectioned into
10 mm-thick sections, which were then mounted onto Super-
Frosted-plus slide (Fisher). In preparation for in situ S100A7
receptor staining, tissue sections or cultured cells or platelets were
fixed for 1 hour in 4% paraformaldehyde at room temperature.
After washing for 5 min in HBS (150 mM NaCl, 20 mM HEPES,
pH 7) followed by rinses (265 min) in HBAH (Complete 16
Hanks Balanced Salt Solution, 0.5 mg/ml BSA, 20 mM HEPES,
pH7), the tissue section was incubated with conditioned media
containing AP-PIF fusion protein at room temperature for
90 minutes. In parallel control experiments, adjacent tissues or
cell sections were incubated with conditioned media containing
AP protein. Thereafter, tissue or cell sections were washed in
HBAH (665 min) and fixed in acetone-formalin (65% acetone,
8% formalin, 20 mM HEPES, pH 7) for 15 sec, and washed again
in HBS (265 min). Tissue sections or cell sections were then
incubated in HBS for 20 min at 65uC. After washing in AP
staining buffer (100 mM NaCl, 5 mM MgCl, 100 mM Tris,
pH 9.5 made fresh before use), S100A7-receptor interaction was
visualized based on development of AP activity. Following brief
fixing (8% formalin in PBS for 20 min) and washing (PBS+10 mM
EDTA), AP-h-S100A7 stained tissue sections were mounted with
aqueous mounting medium and stored in the dark at room
temperature. Immunoreactivities were visualized using the ABC
method (Vector).
Preparation of platelet
Human platelet was prepared from blood collected from a
cognitively normal control case. Freshly collected blood was
centrifuged at low speed (2006g) for 15 min at room temperature
and resulted in platelet-rich plasma (PRP). For analysis of cell-
surface receptor in platelet, 200 ml of the recovered PRP was
plated in 8-well chamber slides, and left overnight. The
supernatant was then removed, and the attached platelet treated
with 100 ml AP or AP-S100A7 expressing culture medium for
24 hours. For analysis of a-secretase activity and ADAM-10 levels
in platelet, 200 ml PRP was collected in 1.5 ml microcentrifuge
tube and treated with 100 nM His-S100A7 recombinant protein
(gift from Nelly Polyak, Harvard Medical School) for 24 hours.
Platelets were collected by centrifugation at 3,0006g for 15 min at
0uC. The resulting platelets were subjected to a-secretase activity
and ADAM-10 measurement as described above. This study was
approved by the Institutional Review Board at James J. Peters
Veterans Affair Medical Center approved.
Generation of double transgenic h-S100A7 mice
h-S100A7 transgenic mice were of the C57B6/SJL background.
The expression of h-S100A7 transgene in transgenic mice is driven
by the cytomegalovirus immediate-early enhancer linked to the
chicken beta-actin promoter. Western blot analysis of serum
collected from h-S100A7 transgenics showed significant higher
levels of immunodetectable S100A7, compared to serum collected
from age-, gender- and strain-matched wild-type control mice.
All mice protocols were approved by the Mount Sinai
Institutional Animal Care and Use Committee.
Statistical analysis
All values are expressed as mean6standard error of the mean
(SEM). Differences between means were analyzed using a two-
tailed Student t test while difference among means were assessed
ANOVA. In all analyses, the null hypothesis was rejected at the
0.05 level. All statistical analyses were performed using the Prism
Stat program (GraphPad Software, San Diego, CA).
Results
Identification of S100A7 as an AD biomarker
In SELDI proteomic studies exploring differentially expressed
protein in the CSF we identified an 11.7-kDa metal-binding
protein whose content which is elevated in the CSF of mild
(CDR1) AD cases (Fig. 1A, B), relative to normally cognitive
controls. Based on this evidence the 11.7 kDa protein species was
isolated from a pool of CSF from AD dementia cases (CDR 2;
moderate AD dementia) and sequence identified as S100A7 based
on MS criteria.
Control immunoadsorption studies using MS-SELDI technol-
ogy confirmed the SELDI-MS evidence and demonstrated that
S100A7 content is elevated in the CSF of moderate AD dementia
cases (CDR2) relative to the normal controls (Fig. 1C, D).
Using an established S1000A7 ELISA assay in the lab we
confirmed that the increased steady-state levels of S100A7
immunoreactive material in the CSF of AD cases (CDR 2–5)
was rather selective since no detectable changes were found in
CSF of cases affected by Parkinson’s disease without dementia and
normal neurological control cases (Fig. 2)
S100A7 mRNA expression is regulated in the brain as a
function of AD clinical progression and amyloid
neuropathology
Based on the evidence that S100A7 protein species in CSF
might be an AD biomarker, we continued to explore the
expression of S100A7 in the AD brain and tested the hypothesis
that S100A7 expression may be regulated as a function of clinical
dementia or neuropathology.
We found that S100A7 mRNA expression increases in the brain
(frontal cortex; BM8) as a function of AD dementia assessed by
CDR (Fig. 3A). Most importantly, we found that S100A7 mRNA
expression selectively correlated with AD amyloid plaque (Fig. 3B),
but not neurofibrillar tangle as assessed by CERAD neuropathol-
ogy score (Fig. 3C). These changes in S100A7 expression in the
frontal cortex of the brain were highly selective because no
detectable changes were visualized in the occipital cortex (BM17,
data not shown).
S100A7 is involved in the ‘‘non-amyloidogenic’’ a-
secretase activity in AD
Since S100A7 expression is regulated in the AD brain as a
function of clinical dementia as well as amyloid-plaque neuropa-
thology, we hypothesized that S100A7 might play an important
role in amyloidogenesis eventually influencing cognitive functions.
We found that the adenoviral expression human h-S100A7 in
cultured Chinese hamster ovary (CHO) cells (see inset Fig. 4C),
stably expressing mutant APPswe, significantly attenuated the
content of amyloidogenic Ab1–42 peptides in the conditioned
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of the content of soluble (s)APPa relative to total sAPP (sAPPa/
total sAPP) in the conditioned medium, which is an indication of
‘‘non-amyloidogenic’’ a-secretase activity (Fig. 4B). Consistent
with this evidence, using a commercially available a-secretase
activity assay,
27 we confirmed that exogenous h-S100A7 expres-
sion in CHO-APPswe promotes a-secretase activity, based on
quantification of fluorescent signal from specific a-secretase
cleaved substrates in vitro (Fig. 4C).
In light of recent evidence indicating that the proteinase
ADAM-10 (a disintegrin and metalloproteinase) may act as an a-
secretase [28], we continued to explore the potential role of
S100A7 in the regulation of ADAM-10 in cultured CHO-APPswe
cells. We found that exogenous hS100A7-mediated ‘‘non-amyloi-
dogenic’’ a-secretase activity coincided with a selective .two fold
accumulation of cellular ADAM-10 precursor protein (85 kDa)
and its processed mature form of ADAM-10 (60 kDa), as assessed
by western blot assay (Fig. 4D).
The 62-kDa mature ADAM-10 protein species is known to act
as an a-secretase in vitro and to cleave Ab-derived peptides at
leucine16 [29]. No detectable change in ADAM-9 and ADAM-17
(TACE) expression was found in S100A7 expressing CHO-APPswe
cells (Fig. 4E). In control studies we found that b-secretase activity
(assessed by commercial assay) [27] or c-secretase activity (assessed
by quantitation of c-CTF generation) [23] are not affected by h-
S100A7 expression in CHO-APPswe cells (data not shown).
Exogenous expression of human S100A7 reduced
generation of Ab peptides in primary neuron cultures
from Tg2576 mice, coincidental to induction of a-
secretase activity
Consistent with the observations in CHO-APPswe cells, using
activity assays as discussed above we confirmed that viral expression
of exogenous h-S100A7 expression in primary neuron cultures
derived from Tg2576 embryos promotes cellular a-secretase activity
coincidentalwith significant attenuation of accumulation Ab1–40and
Ab1–42 peptide content in the conditioned medium 48 hrs after
infection, relative to Lac-Z infected neurons (Fig. 5A–C). Interest-
ingly the h-S100A7 mediated induction of a-secretase activity
coincidental with attenuation of Ab peptide accumulation in the
conditioned medium is prevented by co-treatment of cortico-
hippocampal neurons with the ADAM-10 inhibitor, TIMP-1
(Fig. 5A–C) further supporting the hypothesis that the S100A7-
Figure 1. Identification of biomarkers in the CSF of AD cases. For the study, CSF was collected by lumbar puncture (n=4 per group),
centrifuged (1,3006g) at 4uC, aliquoted and stored at 280uC. 4 mg of CSF proteins from each case was analyzed by SELDI technology using the IMAC-
Cu
++ protein chip; only Cu
++-binding proteins are analyzed using this chip. A, SELDI retention map; ‘‘peaks’’ represent individual detected proteins,
and the area under the peak represents the signal intensity. Reference molecular sizes are indicated across the bottom of the panel. B, molecular
weight frequency scatter graph indicating the quantitative distributions of individual Cu
++-binding protein for each of the cases analyzed. Peak #3
shows the levels of expression of the 11.7-kDa species in the AD dementia and normal cognitive controls. C, western blot confirmation of elevated
S100A7 contents in the CSF of AD cases. Bar graph represents mean6SEM and is shown as % of the control group; *P,0.05, by 2 way t-test, n=4–7
per group. Inset: representative S100A7 western blot analysis. D. Immunoadsorption with the S100A7 antibody showed no visible bands in a western
blot.
doi:10.1371/journal.pone.0004183.g001
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pal neurons is ADAM-10 dependent.
In further control studies we found that the h-S100A7
overexpression in cortico-hippocampal neurons derived from
Tg2576 embryos did not affect the cellular contents of either the
precursor or the mature (catalytically active) ADAM-17 another
members of the ADAM proteinase family ADAM-17 (TACE),
which can also act as a-secretase in certain conditions [29,31]
(Data not shown).
S100A7 influences a-secretase and b-amyloid steady-
state levels through mechanisms that involve p42/44
MAPK (Erk1/2) and PKC signaling in primary cortico-
hippocampal neuron cultures
There is evidence that a-secretase–associated sAPPa secretion is
regulated in a PKC-dependent or -independent fashion that
involves activation of tyrosine kinase [32]. Moreover, the MAPK
signaling pathway was recently implicated in both PKC and
tyrosine kinase receptor regulation of APP processing [33,34]. We
therefore explored which, if any, of these kinases is involved in
mediating the action of S100A7 on sAPPa release.
We found that, coincidental with the increasing level of a-
secretase activity secretion as well as the reduction of Ab1–42 level
as shown in primary cortico-hippocampal neuron cultures (see
Fig. 5), exogenous expression of h-S100A7 promoted Erk1/2
(Fig. 6A) and PKC-p (Fig. 6B) phosphorylation relative to controls
LacZ expressing cells, assessed by western-blotting analysis using a
anti-phospho-p42/p44 MAPK or anti phosphor-PKC (pan)
antibody. No detectable change in total p42/44MAPK, total
PKCa (or control actin) concentrations were found after h-
S100A7 expression (Fig. 6A, B).
To further investigate the observation that S100A7 influences a-
secretase activity and Ab steady-state levels in the conditioned
medium in cortico-hippocampal neuron cultures through mech-
anisms that involve p42/44 MAPK (Erk1/2) and PKC-signaling
pathways, neuron cultures were pre-incubated for 30 min with
PD98059 (10 mM) or GF109203X (5 mM), which are select
inhibitors of p42/44 MAPK or PKC, respectively, and then
infected cells with adenoviral h-S100A7 or adenoviral lacZ for
24 hours.
We found both PD98059 and GF109203X prevented
hS100A7–mediated changes in a-secretase activity (Fig. 7A, D)
in cell lysates, Ab1–42 steady-state levels in the conditioned
medium (Fig. 7B, E), and sAPPa secretion in conditioned media
(Fig. 7C, F), relative to the Lac-Z expressing control neuron
cultures. These findings indicate that PKC- and MAPK-
dependent signaling pathways are involved in S100A7-mediated
stimulation of a-secretase activity and reduction of Ab amylodosis.
Detection of cell-surface S100A7 receptor(s) in neuronal
cells, cultured CHO-APPswe cells, and mouse brain
S100A7 is known to be both a cytoplasmic and but also a
secreted protein in certain peripheral cells [26]. Based on this
consideration and on our observations, we hypothesized that
S100A7 in the brain and in biological fluids, e.g. CSF may
promote ‘‘non-amyloidogenic’’ a-secretase activities through an
autocrine/paracrine function. To test this hypothesis and to
provide supportive evidence for promotion of ‘‘non-amyloido-
Figure 2. Selective elevation of S100A7 protein in the CSF of AD
cases relativeto neurologicallynormalcontrolcases orPDcases.
Monoclonal anti-human S100A7 antibody was used in a single antibody
ELISA assay to quantify the content of S100A7 immunoreactivity in the
CSF of non-medicated AD (n=49), Parkinson’s disease (n=21), and
neurological normal control (n=10) cases. In this study, microtiter wells
were coated with the antigen (0.5 ml CSF diluted 200-fold), dissolved in
100 ml of Buffer 42 (30 mM NaHCO3,7 0 m MN a 2CO3, 0.05% NaN3,
pH 9.6), and incubated at 4uC overnight. Data are shown as a scatter
plot. *P,0.05 vs. neurological controls or PD cases by one-way ANOVA.
doi:10.1371/journal.pone.0004183.g002
Figure 3. S100A7 mRNA expression in AD brain increases as a function AD dementia and amyloid neuropathology. A, S100A7 content
in BM 8 (quantified by real-time RT-PCR and normalized by cyclophilin) as a function of CDR representing cognitive normalcy (CDR 0), questionable
dementia (CDR 0.5), mild dementia (CDR 1), and severe dementia (CDR 5). Data are expressed as mean6SEM and are shown as percent of CDR 0
group. B, C, S100A7 mRNA expression as a function of b-amyloid NP plaque and NFTs neuropathology, respectively, in accordance with the CERAD
four-point scale for AD. Data represent mean6SEM and are shown as percent relative to CERAD 0 group, respectively; in A–C statistics were
calculated by two-way ANOVA followed by Dunnett’s t-test vs. control; *P,0.05. The number inside each bar indicates number of cases analyzed.
doi:10.1371/journal.pone.0004183.g003
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examined a potential interaction of S100A7 with cell-surface
receptor(s) in Tg2576 neuronal cultures.
Using an established N-terminal alkaline phosphate (AP) C-
terminal S100A7 fusion protein as a ligand for in situ receptor-
binding assays [25], we found strong AP-S100A7 binding activity
in in vitro cortico-hippocampal neuron cultures primarily localized
to neuropil and neuronal cell contours supporting for the first time
the expression of cell-surface S100A7 receptor(s) in neuronal cells.
Control cultures treated with AP alone resulted in background
staining, as expected (Fig. 8A).
As expected, cell-surface S100A7 binding activity was detected
in cultured CHO-APPswe cells (Fig. 8B) as well as and in the
granular layer of mouse hippocampal formation with a preferen-
tial distribution with the neuropil (Fig. 8C); AP treated samples
resulted in background staining, as expected (Fig. 8B.C).
The study support the hypothesis that secreted S100A7 in the
brain, by interaction with cell-surface receptor(s), might promote
activation of ADAM-10, ultimately resulting in the promotion of
‘‘non-amyloidogenic’’ a-secretase activity in neuronal cells.
Exogenous S100A7 expression in platelets promotes
‘‘non-amyloidogenic’’ a-secretase activity
A recent study documented significantly reduced levels of
ADAM-10 in circulating blood platelet cells of AD patients
compared to age-matched control cases [35]. Although the
mechanisms leading to reduction of ADAM-10 in circulating
platelets in AD is presently not known, in view of the activity of
ADAM-10 as an a-secretase, it is conceivable that the presence of
lower levels of ADAM-10–mediated ‘‘non-amyloidogenic’’ a-
secretase activity in peripheral cells such as circulating platelets
could eventually contribute to amyloid neuropathogy in AD.
Based on this hypothesis, and on the presence of S100A7 in the
serum (Pasinetti, unpublished observation), we initiated a series of
studies to test the feasibility of using S100A7 as a means of
promoting non-amyloidogenic’’ a-secretase activity as potential
novel therapeutic approach in AD.
We first found that AP S100A7 binds intensely with purified
human platelet cells, relative to AP control treated platelets
(Fig. 9A). Thus, similar to neuronal cells, it is likely that platelet
cells also express a cell-surface receptor. Based on this encouraging
Figure 4. S100A7 expression attenuates b-amyloid peptide generation in cultured CHO-APPswe cells. Cells were infected with adeno
human h-S100A7 virus or lacZ virus for 24 or 48 hours at 10 multiplicities of infection (MOI=10). A, Amyloid-beta1–42 peptide content in the condition
media was analyzed using a commercial ELISA assay. B, western blot analysis of soluble (s)APPa (6E10 antibody/total sAPP content (22C11 antibody)
in the culture media. C, a-secretase activity of cell lysate assessed based on monitoring cleavage of a specific synthetic a-secretase peptide substrate
using an a-secretase activity kit following manufacturer’s instructions (R&D Systems). Inset, representative western blot analysis of h-S100A7 in culture
media confirming the secretory feature of S100A7; Mature ADAM-10 (D) and mature ADAM-9 or ADAM-17 (TACE) (E) were assessed by western blot
analysis. Insets, representative western blot analysis of precursor and mature ADAM-10 (D) and ADAM-9 or ADAM-17 (E). A–C, values represent
mean6SEM and are shown as percent of LacZ control infected cells; n=3 independent cultures per group from two independent studies; *P,0.05 by
two-way t-test.
doi:10.1371/journal.pone.0004183.g004
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paracrine role of S100A7 in modulating ADAM-10 in platelets
through interaction with the S100A7 cell-surface receptor in
platelets. We found that incubation of platelets with h-S100A7
(100 nM) leads to ,two fold induction of ‘‘non-amyloidogenic’’ a-
secretase activity (Fig. 9B) and elevated levels of ADAM-10
precursor as well as its mature catalytically active form (Fig. 9C).
Based on this evidence we initiated the generation of transgenic
mice with constitutive overexpression of S100A7 in the brain to
test the hypothesis that S100A7 may promote ‘‘non-amyloido-
Figure 5. Adenovirus-mediated overexpression of hr-S100A7 modulated b- amyloid generation in primary Tg2576 cortical neurons
cultures. Primary cortical neuronal cultures generated from hemizygote E14 Tg2576 mouse embryos were maintained in a serum-free Neurobasal
media in the presence of B27-supplement (GIBCO) essentially as previously described [42]. Seven-day-old Tg2576 neuronal cultures were infected
with adeno-S100A7 virus (or adeno-LacZ virus as control) with a dose of virus at 10 MOI. (A) Ab1–40 and Ab1–42 (B) peptide contents in the condition
media 48 hrs after viral infection was analyzed using commercial ELISA assays. C, a-secretase activity of neuronal cell lysate using the a-secretase
activity kit (R&D Systems).
doi:10.1371/journal.pone.0004183.g005
Figure 6. h-S100A7 adenoviral infection in primary cortico-hippocampal neuron cultures derived from Tg 2576 embryos coincides
with activation of p42/44MAPK and PKC signaling. A,B, cortico-hippocampal neuron cultures derived from Tg2576 embryos were infected
with LacZ or h-S100A7 adenovirus for 24 hours at 10 MOI. The phosphorylation of p42/44 MAPK and PKC were analyzed in cell lysate and detected by
pTpY
185/187-p42/44 MAPK antibody or total p42/44 MAPK antibody (A) and phosphor-PKC (pan) antibody or PKCa antibody (B). In this study, tissue-
culture dishes were placed on ice (4uC) and, following the removal of conditioned media, cells were immediately collected in ice-cold 16SDS-sample
buffer containing protease inhibitors. Data represent mean6SEM of determinations made in three separate cultures; n=3 to 4 per culture; two-tailed
Dunnett’s t-test vs. LacZ infection: *P,0.05, two-way t-test.
doi:10.1371/journal.pone.0004183.g006
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potential therapeutic role of S100A7 expression in the brain on
AD-type amyloid neuropathology.
a-secretase activity increases in transgenic h-S100A7
mice brain
Based on the hypothesis that S100A7 might represent a
potential promoter of ‘‘non-amyloidogenic’’ a-secretase activity
in the brain precluding Ab peptide generation we generated
hS100A7 transgenic mice to test the hypothesis that S100A7 may
ultimately influence AD-type neuropathology/neurodegeneration.
The expression of h-S100A7 transgene in these transgenic mice
is driven by the cytomegalovirus immediate-early enhancer linked
to the chicken b-actin promoter. h-S100A7 transgenic mice were
generated and maintained using the C57B6/SJL stain back-
ground.
As expected, we found significant higher levels of immunode-
tectable S100A7, relative to age-, gender- and strain-matched
wild-type (WT) control mice assessed by Western blot analysis
(Fig. 10A). Moreover, we assessed for a potential role of hS100A7
expression in modulating a-secretase activity in our h-S100A7
mice. Excitingly, we found significant elevation of ‘‘non-amyloi-
dogenic a-secretase activity in the brain of h-S100A7 transgenics
compared to WT mice (Fig. 10B). The study suggest that
therapeutic promotion of S100A7 expression in the brain may
promote ‘‘non-amyloidogenic’’ a-secretase activity in the brain
ultimately precluding generation of amyloidogenic Ab peptides in
the brain.
Discussion
Diagnosis and monitoring of AD and the related dementias
have long depended principally on clinical examination, especially
cognitive testing. Establishment of biomarkers, which might assist
in diagnosis or tracking of disease progression, would be a highly
valuable addition to the care of patients. Such biomarkers are
potentially available from body fluids and tissues as well as from
brain imaging data. As specific disease-modifying therapies for
Alzheimer’s disease are developed, biomarkers may improve
diagnostic accuracy and facilitate clinical trials, allowing a better
gauge of treatment response [36].
Discovery-based proteomics discussed in this study has greatly
enhanced our ability to reveal candidate proteins involved in
Figure 7. h-S100A7-mediated promotion of a-secretase activity and sAPPa secretion and decreased amyloid-beta1–42 level are
prevented by p42/44MAPK and PKC signal-transduction inhibitors. In this study cortico-hippocampal neuron cultures derived from Tg2576
embryos were pre-incubated for 30 min with vehicle alone or with PD98059 (10 mM) (A–C) or with GF109203X (5 mM) (D–F). Following the
preincubation time, the cells were infected with LacZ or h-S100A7 adenovirus for 24 h at 10 MOI. A, resulting cell lysates were analyzed for a-
secretase activity. B, C, proteins released into the conditioned media were collected and analyzed for b-amyloid by ELISA or sAPP a and total sAPP by
western blotting. Data represent mean6SEM of determinations made in two separate cultures; n=3 to per culture; two-tailed Dunnett’s t-test vs.
control (vehicle treated): *P,0.05.
doi:10.1371/journal.pone.0004183.g007
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extremely challenging to validate these putative markers largely
because of the enormous complexity of biological systems,
heterogeneity of humans, and/or lack of high-throughput
technology [37].
The identification of S100A7 as an AD biomarker could be a
major advance in the understanding and treatment of AD, with a
number of potential applications. Since S100A7 content is
elevated in the CSF of AD dementia cases compared to
neurological control cases, and these elevated S100A7 levels in
the CSF selectively identify AD clinical severity, S100A7 could be
a biomarker that quickly diagnoses AD before clinical signs have
developed, allowing for early symptomatic treatment and the
ability to chart the course of the disease accurately.
Figure 8. In situ S100A7 receptor binding activities in primary embryonic cortical neurons derived from Tg2576 mice, CHO-APPswe
cells, and mouse brain. Seven-day-old Tg2576 neuronal cultures (A), CHO-APPswe cells (B) and 10 mm frozen tissue sections from mouse brain (C)
were incubated with AP-S100A7 fusion protein or control AP protein. Blue (A) and purple (B, C) staining detects interaction between AP-S100A7 with
a putative S100A7 receptor. Length bar=10 mm. n=3 independent cultures per group from two independent experiments.
doi:10.1371/journal.pone.0004183.g008
Figure 9. S100A7 receptor-binding activity in human platelets and modulation of a-secretase activity and ADAM-10 expression in
platelet cells by S100A7 exposure. In this study, human platelet was prepared from blood collected from a cognitively normal control case.
Cultured platelets were used for AP-S100A7 ligand-binding assay (bottom); parallel study using AP served as control staining (A). B, C, cultured
platelets were treated with 100 nM h-S100A7 for 24 hours; parallel platelet cultures treated with vehicle served as controls. B, a -secretase activity in
platelet lysates assessed using the a-secretase activity kit (R&D Systems). C, precursor and mature ADAM-10 content assessed by western blot
analysis. Inset, representative western blot analysis of precursor and mature ADAM-10 in platelet lysates. B, C, values represent mean6SEM and are
shown as percent of control cells; n=3 independent cultures per group. *P,0.05, two-tailed Student t-test, hr-S100A7 vs. control group.
doi:10.1371/journal.pone.0004183.g009
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the brain as a function of AD dementia and selectively
correlated with AD amyloid plaque, but not neurofibrillary
tangle, in a highly selective manner. This opens the question of
whether S100A7 might be involved in amyloidogenesis. Our
investigations suggest that it is, through activation of alpha-
secretase activity. This S100A7-mediated anti-amyloidogenic
activity coincided with the accumulation of both ADAM-10
precursor protein and the processed mature form. There was no
detectable change in ADAM-9 and ADAM-17 (TACE)
expression.
Ab is thought to play a crucial role in the pathogenesis of AD. It
is generally thought that the a-secretase pathway mitigates b-
amyloid formation in the normal brain. The ‘‘non-amyloidogenic’’
a-secretase pathway starts with APP cleavage by a-secretase,
which cuts within the b-amyloid domain and thus precludes b-
amyloid generation. Several studies have suggested that a-
secretases ADAM-9, ADAM-10, and ADAM-17, which belong
to the ADAM (a disintegrin and metalloprotease) family of
membrane-anchored cell-surface proteins, may be involved [38].
We do not know the mechanism by which the levels of ADAM-
10 in circulating blood platelet cells of AD patients are reduced.
But since ADAM-10 is an a-secretase, it is conceivable that these
lower levels of anti-amyloidogenic a-secretase activity in periph-
eral cells could be caused by these reduced levels of ADAM-10.
This could be part of the amyloid neuropathology in AD. Our
finding showing .two fold promotion in ‘‘non-amyloidogenic’’ a-
secretase activity and elevated levels of ADAM-10, following
expression of exogenous hS100A7 to platelet cells supports this
hypothesis.
b-o rc -secretase activity is not affected by human S100A7
expression in either CHO-APPswe cells or in primary cortico-
hippocampal neurons derived from Tg 2576 embryos. This in
vitro evidence strongly suggests that the elevation of S100A7
expression in the brain of patients with AD might reflect a novel
protective anti-amyloidogenic compensatory mechanism in
response to the rampant AD brain amyloidogenesis. The
mechanism by which S100A7 influences a-secretase and Ab
levels could involve p42/44 MAPK (Erk1/2) and PKC signaling.
Our studies indicate that S100A7 increased Erk1/2 or PKC
phosphorylation. Also, inhibitors of p42/44 MAPK or PKC
have the effect of preventing h-S100A7 from influencing a-
secretase activity.
Thus, it may be feasible to use S100A7 to promote anti-
amyloidogenic a-secretase activity in peripheral cells. We tested
this potential of S100A7 in promoting anti-amyloidogenic activity
in the periphery and in the brain, in vivo, and the potential
therapeutic impact on mitigating AD- type amyloid neuropathol-
ogy. Our studies support the hypothesis that secreted S100A7, by
interaction with cell surface receptor(s), can promote activation of
ADAM-10, leading to induction of anti-amyloidogenic activity in
neuronal cells.
We also note that the evidence suggesting that S100A7
associated induction in a-secretase mediated ‘‘non-amyloido-
genic’’ processing might also be consistent with an alternate
biological role of S100A7. For example, in view of the evidence
suggesting that Ab peptides might serve as a redox sensor and
that oxidatively-induced Ab may ultimately attenuate oxidative
stress [39], the changes in S100A7 content in the CSF of AD
brain might be also a reflection of oxidative stress changes
besides Ab content in AD. For example, there is evidence that
oxidative stress per se m a yt e m p o r a l l yp r e c e d ei n c r e a s e si nA b
content in models of AD and that elevation in Ab content might
also function as negative feed-back signal on oxidative stress
responses [40]. Thus, it might be possible that in the future
changes in S100A7 content in AD might be also further explored
to monitor oxidative stress changes associated to altered Ab
metabolism in AD [41].
Collectively, our experimental evidence tentatively suggests that
S100A7 might be causally implicated in APP processing. While
virtually nothing is known about S100A7 in AD pathogenesis,
S1000A7 is a protein unrelated to other members of the S100
family [26], such as S100Bs and its specific role in the AD
including potential modulation of immune-inflammatory respons-
es besides APP processing discussed in this study, is presently
unknown.
Our study provides unprecedented insight into the role of a
novel biomarker of AD clinical dementia, and allow for the further
systematic investigation of a potential novel therapeutic role for
S100A7 via promotion of ‘‘non-amyloidogenic’’ a-secretase/
ADAM-10 mediated responses and possibly through other
mechanisms presently under investigation in our laboratory.
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Figure 10. Elevated a-secretase activity in the brain of h-S100A7 transgenic mice. In this study, h-S100A7 transgenic mice were identified
by dot blot hybridization of tail skin DNA samples with labeled h-S100A7 cDNA (for the h-S100A7 transgene). Expression of serum S100A7 (A) content
in 1-month old h-S100A7 and age-, gender-, and stain-matched WT control mice was assessed by western blot analysis. The brains of h-S100A7
transgenic mice and WT control mice were assessed for a-secretase activity (B) using an activity assay kit (R&D Systems). Values represent mean6SEM
and are expressed as percent of WT control mice group. *P,0.05, two-tailed Student t-test; n=4 per group.
doi:10.1371/journal.pone.0004183.g010
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